A Phase Ib, Open-Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux) in Patients with Non-Small Cell Lung Cancer with Progression Following Prior Erlotinib (Tarceva) or Gefitinib (Iressa)
Conditions
Non Small Cell Lung Cancer
What is the purpose of this trial?
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Boehringer Ingelheim Pharmaceuticals
- Dates:
- April 2011
- Last Updated:
- Study HIC#:
- 1010007517
Clinicaltrials.gov ID: Yale3785320
For more information about this trial, contact:
Investigator
Scott Gettinger, MD
Principal Investigator
